Lv47
490 积分 2023-03-15 加入
Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
5天前
已完结
CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)
5天前
已完结
Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
5天前
已完结
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study
5天前
已完结
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study
5天前
已关闭
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study
5天前
已关闭
[Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma]
6天前
已完结
Emerging Therapies for the Management of Richter Transformation
19天前
已完结
Richter transformation—is there light at the end of this tunnel?
19天前
已关闭
Richter transformation—is there light at the end of this tunnel?
19天前
已关闭
BCA法检测组分百日咳疫苗中间品蛋白含量的可行性评价
1年前
已采纳
皖公网安备34019202002308
